Moleculin Biotech (MBRX) Competitors $0.68 +0.02 (+3.31%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$0.66 -0.01 (-1.83%) As of 05:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MBRX vs. ANRO, EPIX, EXOZ, CABA, BYSI, ELUT, MIST, CELU, IPA, and SRZNShould you be buying Moleculin Biotech stock or one of its competitors? The main competitors of Moleculin Biotech include Alto Neuroscience (ANRO), ESSA Pharma (EPIX), eXoZymes (EXOZ), Cabaletta Bio (CABA), BeyondSpring (BYSI), Elutia (ELUT), Milestone Pharmaceuticals (MIST), Celularity (CELU), ImmunoPrecise Antibodies (IPA), and Surrozen (SRZN). These companies are all part of the "pharmaceutical products" industry. Moleculin Biotech vs. Its Competitors Alto Neuroscience ESSA Pharma eXoZymes Cabaletta Bio BeyondSpring Elutia Milestone Pharmaceuticals Celularity ImmunoPrecise Antibodies Surrozen Moleculin Biotech (NASDAQ:MBRX) and Alto Neuroscience (NYSE:ANRO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings. Does the media prefer MBRX or ANRO? In the previous week, Alto Neuroscience had 19 more articles in the media than Moleculin Biotech. MarketBeat recorded 24 mentions for Alto Neuroscience and 5 mentions for Moleculin Biotech. Alto Neuroscience's average media sentiment score of -0.06 beat Moleculin Biotech's score of -0.31 indicating that Alto Neuroscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moleculin Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Alto Neuroscience 0 Very Positive mention(s) 0 Positive mention(s) 21 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, MBRX or ANRO? Moleculin Biotech has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Comparatively, Alto Neuroscience has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500. Do insiders and institutionals hold more shares of MBRX or ANRO? 15.5% of Moleculin Biotech shares are owned by institutional investors. 2.1% of Moleculin Biotech shares are owned by company insiders. Comparatively, 11.1% of Alto Neuroscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is MBRX or ANRO more profitable? Alto Neuroscience's return on equity of -39.35% beat Moleculin Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Moleculin BiotechN/A -278.80% -100.11% Alto Neuroscience N/A -39.35%-33.86% Which has stronger earnings and valuation, MBRX or ANRO? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMoleculin BiotechN/AN/A-$21.76MN/AN/AAlto NeuroscienceN/AN/A-$61.43M-$2.34-1.31 Do analysts prefer MBRX or ANRO? Moleculin Biotech currently has a consensus target price of $4.00, suggesting a potential upside of 490.49%. Alto Neuroscience has a consensus target price of $8.50, suggesting a potential upside of 177.78%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, research analysts clearly believe Moleculin Biotech is more favorable than Alto Neuroscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moleculin Biotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Alto Neuroscience 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57 SummaryAlto Neuroscience beats Moleculin Biotech on 7 of the 11 factors compared between the two stocks. Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBRX vs. The Competition Export to ExcelMetricMoleculin BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.81M$2.98B$5.48B$9.57BDividend YieldN/A2.46%3.99%4.17%P/E RatioN/A17.9729.8525.14Price / SalesN/A262.52422.3397.16Price / CashN/A41.8335.9458.58Price / Book0.387.238.125.59Net Income-$21.76M-$54.43M$3.26B$265.48M7 Day Performance1.85%0.22%0.68%1.22%1 Month Performance29.92%5.59%2.46%0.39%1 Year Performance-69.35%9.98%27.99%23.47% Moleculin Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBRXMoleculin Biotech2.6696 of 5 stars$0.68+3.3%$4.00+490.5%-69.2%$19.81MN/A0.0020Upcoming EarningsShort Interest ↑Gap DownANROAlto Neuroscience1.664 of 5 stars$3.10+1.5%$8.50+174.6%-65.5%$83.78MN/A-1.32N/AUpcoming EarningsEPIXESSA Pharma1.3453 of 5 stars$1.88+0.3%$2.00+6.7%-58.2%$83.23MN/A-2.9850Upcoming EarningsEXOZeXoZymesN/A$9.93-1.9%N/AN/A$83.11M$70K0.0029News CoverageCABACabaletta Bio1.8617 of 5 stars$1.64+4.1%$14.43+782.5%-76.3%$82.96MN/A-0.6450News CoveragePositive NewsEarnings ReportBYSIBeyondSpringN/A$2.03+1.0%N/A+13.3%$81.85M$1.75M0.0080Gap UpELUTElutia3.0515 of 5 stars$1.95+6.0%$8.00+310.3%-30.3%$80.18M$24.38M-1.01180Positive NewsMISTMilestone Pharmaceuticals2.0431 of 5 stars$1.49+1.7%$7.00+371.4%+13.5%$79.39M$1M-1.9030CELUCelularity0.0723 of 5 stars$3.30+3.4%N/A+17.3%$79.04M$54.22M-1.25220IPAImmunoPrecise Antibodies2.16 of 5 stars$1.73-0.3%$4.00+131.9%+134.2%$78.94M$18.16M-1.4980Short Interest ↑Gap UpSRZNSurrozen1.8195 of 5 stars$9.05-2.2%$38.50+325.6%+25.4%$77.43M$10.65M-0.3680Upcoming EarningsGap Down Related Companies and Tools Related Companies ANRO Competitors EPIX Competitors EXOZ Competitors CABA Competitors BYSI Competitors ELUT Competitors MIST Competitors CELU Competitors IPA Competitors SRZN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MBRX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moleculin Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
